Tibet Cheezheng Tibetan Medicine Co Ltd
The company maintains a strong liquidity position, with a current ratio of 2.57, indicating sufficient short-term assets to cover liabilities. However, its net cash position is negative after subtracting total debt, signaling potential liquidity risk. The debt-to-equity ratio of 0.19 suggests a conservative capital structure, with limited leverage exposure. Free cash flow of CNY 182.1 million supports operational flexibility, though capital expenditures of CNY -153.1 million indicate ongoing investment in infrastructure or asset maintenance. Profitability metrics show a return on equity (ROE) of 13.11% and a return on assets (ROA) of 9.38%, both exceeding the typical thresholds for pharmaceutical firms. Gross profit of CNY 2.01 billion and operating income of CNY 768.5 million reflect strong cost control and pricing power. However, the company’s net income of CNY 648.4 million is lower than gross profit, suggesting elevated operating or non-operating expenses. Geographic and segment exposure is concentrated in the Chinese domestic market, with no disclosed international revenue. The company operates a single business segment focused on Tibetan medicine, which may limit diversification benefits. Revenue concentration in a single product line or region could expose the company to regulatory or demand shocks. Growth trajectory appears stable, with revenue of CNY 2.42 billion in the latest period. While no forward-looking revenue guidance is provided, the company’s free cash flow and operating cash flow of CNY 729.7 million suggest capacity for reinvestment or shareholder returns. However, the absence of disclosed revenue growth rates or segment-specific growth plans limits visibility into future performance. Risk factors include medium liquidity risk due to negative net cash and a low dilution risk score. The company has not disclosed any recent share issuance or dilution events, and shares outstanding remain unchanged between basic and diluted measures. Governance and ESG scores are mixed, with a governance pillar score of 28.65 and a high ESG controversies score of 100.00, indicating potential reputational or regulatory exposure. Recent events include no disclosed earnings calls, regulatory filings, or material business developments. The company’s ESG controversies score suggests unresolved issues, though the nature of these is not specified in the input data.
Business. Tibet Cheezheng Tibetan Medicine Co Ltd develops, produces, and sells traditional Tibetan medicines, primarily targeting the Chinese domestic market.
Classification. The company is classified under the Healthcare sector, specifically in the Pharmaceuticals & Medical Research business sector, with a high confidence level of 0.92.
- Strong liquidity with a current ratio of 2.57 but negative net cash after debt.
- Conservative leverage with a debt-to-equity ratio of 0.19.
- High ROE (13.11%) and ROA (9.38%) indicate strong profitability.
- Revenue and segment concentration in the Chinese domestic market.
- Mixed ESG scores, with a high controversies score and low governance score.
- --
- # RATIONALES
- ```json
- Net cash is negative after subtracting total debt.